Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Smidt

Nurse Practitioner, Family Ringgold, GA Nurse Practitioner

NPI 1356699169 CMS profile 10418060

4700 Battlefield Pkwy Ste 300, Ringgold, GA 30736

Open in the dashboard

General payments

$14,245

582 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Smidt of Ringgold, GA is reported in the CMS Open Payments database as having received $14,245 across 582 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,365 157
2024 General $5,109 145
2023 General $3,430 147
2022 General $1,644 89
2021 General $697 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Smidt
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Amanda Smidt were reported at $3,365. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Amanda Smidt Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $697 $124 $35–$379 $132
2022 $1,644 $141 $44–$430 $149
2023 $3,430 $154 $49–$476 $160
2024 $5,109 $165 $51–$504 $164
2025 $3,365 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,031 51 payments
  2. Novartis Pharmaceuticals Corporation $1,770 101 payments
  3. AbbVie, Inc. $1,623 69 payments
  4. E.R. Squibb & Sons, L.L.C. $1,304 54 payments
  5. Regeneron Healthcare Solutions, Inc. $1,249 50 payments
  6. Lilly USA, LLC $1,165 51 payments
  7. Genzyme Corporation $1,088 41 payments
  8. UCB, Inc. $666 23 payments
  9. Pfizer Inc. $610 26 payments
  10. Dermavant Sciences, Inc. $535 22 payments
  11. Other $2,204 94 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,519 573 payments
  2. Consulting Fee $1,063 1 payment
  3. Education $500 7 payments
  4. Travel and Lodging $163 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $1,929 44 payments
  2. SOTYKTU $1,219 53 payments
  3. DUPIXENT $1,115 42 payments
  4. RINVOQ $852 22 payments
  5. COSENTYX $704 46 payments
  6. LIBTAYO $659 26 payments
  7. TALTZ $582 34 payments
  8. Bimzelx $542 17 payments
  9. VTAMA $535 22 payments
  10. CIBINQO $480 23 payments
  11. Other $5,419 294 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,207

Median for Nurse Practitioner: 389

Drug cost

$768,777

Median for Nurse Practitioner: $21,885

Branded share of claims

8.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 16 $337,501
Dupixent Pen Dupilumab Brand 47 $175,705
Cosentyx Unoready Pen Secukinumab Brand 11 $145,216
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $79,283
Fluorouracil Generic 157 $12,415
Clobetasol Propionate Generic 165 $5,933
Ketoconazole Generic 259 $4,768
Triamcinolone Acetonide Generic 217 $2,161
Minocycline Hcl Generic 78 $1,670
Valacyclovir Valacyclovir Hcl Brand 23 $775

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$107,109

Of which drugs: $237

Medicare patients

781

Average age 74

Services billed

5,014

469 women, 312 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 30%
Ischemic heart disease 29%
Chronic kidney disease 22%
Depression 18%
Atrial fibrillation 15%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 45 381 $237

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$1,527 — —
DUPIXENT
$506 47 —
SOTYKTU
$393 — —
LIBTAYO
$381 — —
VTAMA
$307 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

582 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record